158982-15-1

Basic information

• Product Name: N9-ISOPROPYL-OLOMOUCINE
• Synonyms: 2-[2'-HYDROXYETHYLAMINO]-6-BENZYLAMINO-9-ISOPROPYLPURINE;N9-ISOPROPYL-OLOMOUCINE;OLOMOUCINE, N9-ISOPROPYL-;ISOPROPYL-OLOMOUCINE;2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-ethanol;N9-Isopropyl-olomoucine
• CAS NO: 158982-15-1
• Molecular Formula: C17H22N6O
• Molecular Weight: 326.4
• Mol File: 158982-15-1.mol
• Article Data: 2

Chemical Properties

• Melting Point: 145-148℃
• Boiling Point: 574.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.30
• Storage Temp.: −20°C
• PKA: 14.55±0.10(Predicted)
• CAS DataBase Reference: N9-ISOPROPYL-OLOMOUCINE(CAS DataBase Reference)
• NIST Chemistry Reference: N9-ISOPROPYL-OLOMOUCINE(158982-15-1)
• EPA Substance Registry System: N9-ISOPROPYL-OLOMOUCINE(158982-15-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-53
• WGK Germany: 3
• Hazardous Substances Data: 158982-15-1(Hazardous Substances Data)

Usage

General Description

N9-Isopropyl-olomoucine is a synthetic chemical compound belonging to the olomoucine family, which is known for its inhibitory effects on cyclin-dependent kinases (CDKs). It is primarily used in scientific research to study cell cycle regulation and potential therapeutic targets for cancer treatment. N9-isopropyl-olomoucine has been shown to effectively inhibit the activity of CDK1, CDK2, and CDK5, leading to cell cycle arrest and apoptosis in cancer cells. N9-ISOPROPYL-OLOMOUCINE has also demonstrated potential in overcoming drug resistance and enhancing the efficacy of chemotherapy. However, further research is needed to fully understand its mechanisms of action and potential applications in cancer therapy.

Upstream product

• 141-43-5 ethanolamine 
• 186692-41-1 2-chloro-6-phenylmethylamino-9-iso-propylpurine 
• 203436-45-7 2,6-dichloro-9-isopropyl-9H-purine 
• 5451-40-1 2,6 dichloropurine 
• 39639-47-9 N⁶-benzyl-2-chloroadenine 

Relevant articles and documents

The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic, spectroscopic (IR, ES+ MS, NMR, 57Fe M?ssbauer), theoretical, and biological activity studies

The first FeIII complexes 1-6 with cyclin-dependent kinase (CDK) inhibitors of the type [Fe(Ln)Cl3]·nH2O (n=0 for 1, 1 for 2, 2 for 3-6; L1-L6=C2- and phenyl-substituted CDK inhibitors derived from 6-benzylamino-9-isopropylpurine), have been synthesized and characterized by elemental analysis, IR, 57Fe Mo?ssbauer, 1H and 13C NMR, and ES+ mass spectroscopies, conductivity and magnetic susceptibility measurements, and thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). The study revealed that the compounds are mononuclear, tetrahedral high-spin (S=5/2) FeIII complexes with an admixture of an S=3/2 spin state originating probably from five-coordinated FeIII ions either connecting with a bidentate coordination mode of the CDK inhibitor ligand or relating to the possibility that one crystal water molecule enters the coordination sphere of the central atom in a portion of molecules of the appropriate complex. Nearly spin-only value of the effective magnetic moment (5.82μeff/μB) was determined for compound 1 due to absence of crystal water molecule(s) in the structure of the complex. Based on NMR data and DFT calculations, we assume that the appropriate organic ligand is coordinated to the FeIII ion through the N7 atom of a purine moiety. The cytotoxicity of the complexes was tested in vitro against selected human cancer cell lines (G-361, HOS, K-562 and MCF-7) along with the ability to inhibit the CDK2/cyclinE kinase. The best cytotoxicity (IC50: 4-23μM) and inhibition activity (IC50: 0.02-0.09μM) results have been achieved in the case of complexes 2-4, and complexes 3, 4 and 6, respectively. In addition, the X-ray structure of 2-chloro-6-benzylamino-9-isopropylpurine, i.e. a precursor for the preparation of L1, L4 and L5, is also described.